Related references
Note: Only part of the references are listed.The cure of leukemia through the optimist's prism
Hagop M. Kantarjian et al.
CANCER (2022)
Asciminib: First Approval
Emma D. Deeks
DRUGS (2022)
Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis
Cecilia C. Ayala-Aguilera et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Kincore: a web resource for structural classification of protein kinases and their inhibitors
Vivek Modi et al.
NUCLEIC ACIDS RESEARCH (2022)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2022)
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors
Fadi G. Haddad et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Pacritinib: First Approval
Yvette N. Lamb
DRUGS (2022)
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2022)
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
Funda Meric-Bernstam et al.
CANCER DISCOVERY (2022)
A Comprehensive Overview of Globally Approved JAK Inhibitors
Ahmed M. Shawky et al.
PHARMACEUTICS (2022)
Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors
Chris Arter et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2022)
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2022)
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia
John Mascarenhas
EXPERT REVIEW OF HEMATOLOGY (2022)
Molecular targeted therapy for anticancer treatment
Hye-Young Min et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2022)
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification
Carrow I. Wells et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Abrocitinib: First Approval
Emma D. Deeks et al.
DRUGS (2021)
Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases
Zhouling Xie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
Posttranslational modifications as therapeutic targets for intestinal disorders
Jieun Choo et al.
PHARMACOLOGICAL RESEARCH (2021)
Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
From structure to the dynamic regulation of a molecular switch: A journey over 3 decades
Susan S. Taylor et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Target-Based Evaluation of Drug-Like Properties and Ligand Efficiencies
Paul D. Leeson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Chronic myeloid leukaemia
Jorge Cortes et al.
LANCET (2021)
Trends in kinase drug discovery: targets, indications and inhibitor design
Misty M. Attwood et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
Crowdsourced mapping of unexplored target space of kinase inhibitors
Anna Cichonska et al.
NATURE COMMUNICATIONS (2021)
KinaseMD: kinase mutations and drug response database
Ruifeng Hu et al.
NUCLEIC ACIDS RESEARCH (2021)
New Promise and Opportunities for Allosteric Kinase Inhibitors
Xiaoyun Lu et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase
Paul W. Manley et al.
LEUKEMIA RESEARCH (2020)
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)
Liling Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Defining a new nomenclature for the structures of active and inactive kinases
Vivek Modi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
Katie Bechman et al.
PHARMACOLOGICAL RESEARCH (2019)
Surprising Non-Additivity of Methyl Groups in Drug Kinase Interaction
Barbara Wienen-Schmidt et al.
ACS CHEMICAL BIOLOGY (2019)
The Landscape of Atypical and Eukaryotic Protein Kinases
Georgi K. Kanev et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
Maria Kalyukina et al.
CHEMMEDCHEM (2019)
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Identification of N-{cis-3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminolcyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
Michael L. Vazquez et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials
Fabrice Carles et al.
MOLECULES (2018)
Unexplored therapeutic opportunities in the human genome (vol 17, pg 317, 2018)
Tudor I. Oprea et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
Robert Roskoski et al.
PHARMACOLOGICAL RESEARCH (2018)
The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2018)
The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2018)
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Joseph Schoepfer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2018)
Redefining the Protein Kinase Conformational Space with Machine Learning
Peter Man-Un Ung et al.
CELL CHEMICAL BIOLOGY (2018)
Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview
Peter M. Fischer
MEDICINAL RESEARCH REVIEWS (2017)
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
David Bajusz et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2017)
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
Samuel H. Myers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
KLIFS: a structural kinase-ligand interaction database
Albert J. Kooistra et al.
NUCLEIC ACIDS RESEARCH (2016)
Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods
Sean Ekins et al.
PHARMACEUTICAL RESEARCH (2016)
Molecular inflation, attrition and the rule of five
Paul D. Leeson
ADVANCED DRUG DELIVERY REVIEWS (2016)
Quality guidelines for oral drug candidates: dose, solubility and lipophilicity
Martin K. Bayliss et al.
DRUG DISCOVERY TODAY (2016)
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm
Elias Jabbour et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
A historical overview of protein kinases and their targeted small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2015)
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2015)
Dynamics-Driven Allostery in Protein Kinases
Alexandr P. Kornev et al.
TRENDS IN BIOCHEMICAL SCIENCES (2015)
FDA-approved small-molecule kinase inhibitors
Peng Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
Koji Sasaki et al.
LANCET HAEMATOLOGY (2015)
KLIFS: A Knowledge-Based Structural Database To Navigate Kinase-Ligand Interaction Space
Oscar P. J. van Linden et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery
Timothy J. Ritchie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The role of ligand efficiency metrics in drug discovery
Andrew L. Hopkins et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders
Robert Roskoski
EXPERT OPINION ON DRUG DISCOVERY (2013)
Polyproline-II Helix in Proteins: Structure and Function
Alexei A. Adzhubei et al.
JOURNAL OF MOLECULAR BIOLOGY (2013)
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2013)
Approaches to discover non-ATP site kinase inhibitors
Lori Krim Gavrin et al.
MEDCHEMCOMM (2013)
Deciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
Hiruy S. Meharena et al.
PLOS BIOLOGY (2013)
MEK1/2 dual-specificity protein kinases: Structure and regulation
Robert Roskoski
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
Vandana Lamba et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
The language of SH2 domain interactions defines phosphotyrosine-mediated signal transduction
Bernard A. Liu et al.
FEBS LETTERS (2012)
Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
ERK1/2 MAP kinases: Structure, function, and regulation
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2012)
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Arvin C. Dar et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 80 (2011)
Protein kinase biochemistry and drug discovery
Phillip A. Schwartz et al.
BIOORGANIC CHEMISTRY (2011)
Discovery and Characterization of a Cell-Permeable, Small-Molecule c-Abl Kinase Activator that Binds to the Myristoyl Binding Site
Jingsong Yang et al.
CHEMISTRY & BIOLOGY (2011)
RAF protein-serine/threonine kinases: Structure and regulation
Robert Roskoski
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Defining the conserved internal architecture of a protein kinase
Alexandr P. Kornev et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Through the Gatekeeper Door: Exploiting the Active Kinase Conformation
Fabio Zuccotto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
cAMP-dependent protein kinase: Crystallographic insights into substrate recognition and phosphotransfer
Madhusudan et al.
PROTEIN SCIENCE (2010)
A helix scaffold for the assembly of active protein kinases
Alexandr P. Kornev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The influence of drug-like concepts on decision-making in medicinal chemistry
Paul D. Leeson et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors
Jeffrey Jie-Lou Liao
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism
Alexandr P. Kornev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
BL Roth et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Regulation of the C-Abl and Bcr-Abl tyrosine kinases
O Hantschel et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
A myristoyl/phosphotyrosine switch regulates c-Abl
O Hantschel et al.
CELL (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Protein kinases - the major drug targets of the twenty-first century?
P Cohen
NATURE REVIEWS DRUG DISCOVERY (2002)